Ettore Seregni

11.1k total citations
194 papers, 5.2k citations indexed

About

Ettore Seregni is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Epidemiology. According to data from OpenAlex, Ettore Seregni has authored 194 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 70 papers in Radiology, Nuclear Medicine and Imaging and 49 papers in Epidemiology. Recurrent topics in Ettore Seregni's work include Radiopharmaceutical Chemistry and Applications (48 papers), Neuroendocrine Tumor Research Advances (41 papers) and Lung Cancer Research Studies (30 papers). Ettore Seregni is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (48 papers), Neuroendocrine Tumor Research Advances (41 papers) and Lung Cancer Research Studies (30 papers). Ettore Seregni collaborates with scholars based in Italy, United States and Netherlands. Ettore Seregni's co-authors include Emilio Bombardieri, Antonia Martinetti, Emilio Bajetta, Claudio Chiesa, L. Ferrari, A. Bogni, Marco Maccauro, Flavio Crippa, Giuseppe Procopio and Arturo Chiti and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ettore Seregni

189 papers receiving 5.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ettore Seregni Italy	41	1.8k	1.3k	1.3k	1.3k	842	194	5.2k
Dennis C. Shrieve United States	44	1.3k 0.7×	1.2k 0.9×	1.5k 1.2×	897 0.7×	959 1.1×	187	6.2k
Emilio Bombardieri Italy	47	2.7k 1.5×	1.0k 0.8×	1.8k 1.4×	3.1k 2.4×	1.2k 1.5×	305	8.0k
Martin Gotthardt Netherlands	43	1.7k 0.9×	826 0.6×	1.4k 1.1×	2.3k 1.8×	379 0.5×	209	5.5k
Michael Bamberg Germany	45	1.0k 0.6×	1.3k 1.0×	895 0.7×	1.0k 0.8×	1.5k 1.8×	179	6.9k
Cristina Nanni Italy	49	2.1k 1.2×	1.2k 0.9×	1.2k 0.9×	2.7k 2.1×	948 1.1×	257	7.7k
Tomoyuki Yokose Japan	43	2.6k 1.5×	1.2k 0.9×	905 0.7×	702 0.5×	479 0.6×	272	6.6k
M Tubiana France	46	2.6k 1.5×	884 0.7×	545 0.4×	1.6k 1.3×	787 0.9×	272	7.4k
Enrique Grande Spain	35	2.5k 1.4×	1.1k 0.8×	1.4k 1.1×	202 0.2×	966 1.1×	286	4.6k
Giuseppe Procopio Italy	32	2.7k 1.5×	1.5k 1.1×	986 0.8×	462 0.4×	620 0.7×	360	5.2k
Bin S. Teh United States	48	2.0k 1.1×	1.2k 0.9×	916 0.7×	1.6k 1.2×	589 0.7×	374	8.4k

Countries citing papers authored by Ettore Seregni

Since Specialization

Citations

This map shows the geographic impact of Ettore Seregni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ettore Seregni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ettore Seregni more than expected).

Fields of papers citing papers by Ettore Seregni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ettore Seregni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ettore Seregni. The network helps show where Ettore Seregni may publish in the future.

Co-authorship network of co-authors of Ettore Seregni

This figure shows the co-authorship network connecting the top 25 collaborators of Ettore Seregni. A scholar is included among the top collaborators of Ettore Seregni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ettore Seregni. Ettore Seregni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maccauro, Marco, Matteo Bauckneht, Margarita Kirienko, et al.. (2024). The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging. 52(1). 291–304. 11 indexed citations

Kirienko, Margarita, Giovanni Centonze, Giovanna Sabella, et al.. (2023). FAP expression in alpha cells of Langherhans insulae—implications for FAPI radiopharmaceuticals’ use. European Journal of Nuclear Medicine and Molecular Imaging. 50(10). 3042–3049. 4 indexed citations

Collarino, Angela, Giorgia Garganese, Tina Pasciuto, et al.. (2023). Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review. Gynecologic Oncology. 170. 153–159. 4 indexed citations

Fazio, Nicola, Massimo Falconi, Emanuela Foglia, et al.. (2023). Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group. Advances in Therapy. 41(1). 113–129. 4 indexed citations

Maccauro, Marco, Carlo Spreafico, Gabriele Maffi, et al.. (2022). Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose–Response Analysis with Two Radiological Methods. Cancers. 14(4). 959–959. 10 indexed citations

Luison, Elena, Alessandro Desideri, Federico Iacovelli, et al.. (2021). Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review. Biomedicines. 9(12). 1870–1870. 4 indexed citations

Kirienko, Margarita, et al.. (2021). Deep learning in Nuclear Medicine—focus on CNN-based approaches for PET/CT and PET/MR: where do we stand?. Clinical and Translational Imaging. 9(1). 37–55. 11 indexed citations

Lorenzoni, Alice, Valentina Guadalupi, G Aliberti, et al.. (2021). Update on radioligand therapy with ¹⁷⁷Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. Tumori Journal. 108(4). 315–325. 4 indexed citations

Raimondi, Alessandra, Pierangela Sepe, Mélanie Claps, et al.. (2020). Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Tumori Journal. 106(5). 406–412. 6 indexed citations

10.

Chiesa, Claudio, Marta Mira-Aladrén, Sherrie Bhoori, et al.. (2020). Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship. European Journal of Nuclear Medicine and Molecular Imaging. 47(13). 3018–3032. 42 indexed citations

11.

Bogni, A., et al.. (2019). An improved automated one-pot synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) based on a purification by cartridges. Nuclear Medicine and Biology. 72-73. 11–19. 14 indexed citations

12.

Sternberg, C., Giuseppe Procopio, Ettore Seregni, Roberto Salvioni, & R. Valdagni. (2015). Radium-223 alpha emitter agent in safety study in mCRPC popUlation for long-teRm evaluation (REASSURE). Annals of Oncology. 26. vi64–vi64. 1 indexed citations

13.

Verburg, Frederik A., Markus Luster, Cristina Cupini, et al.. (2013). Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement. Thyroid. 23(10). 1211–1225. 129 indexed citations

14.

Seregni, Ettore, Marco Maccauro, Claudio Chiesa, et al.. (2013). Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. European Journal of Nuclear Medicine and Molecular Imaging. 41(2). 223–230. 75 indexed citations

15.

Castellani, Maria Rita, Ettore Seregni, Marco Maccauro, et al.. (2008). MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?. PubMed. 52(4). 430–40. 34 indexed citations

16.

Chiesa, Claudio, Francesca Botta, Angela Coliva, et al.. (2007). Dosimetry in Myeloablative ⁹⁰ Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results. Cancer Biotherapy and Radiopharmaceuticals. 22(1). 113–120. 17 indexed citations

17.

Devizzi, Liliana, Ettore Seregni, Anna Guidetti, et al.. (2006). High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.. Blood. 108(11). 3047–3047. 9 indexed citations

18.

Maffioli, Lorenzo, L. Mascheroni, Massimo Gasparini, et al.. (1994). Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM).. PubMed. 35(11). 1741–7. 32 indexed citations

19.

Buraggi, G.L., Massimo Gasparini, & Ettore Seregni. (1991). Immunoscintigraphy of colorectal carcinoma with an anti-CEA monoclonal antibody: a critical review. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 18(1). 45–50. 7 indexed citations

20.

Buraggi, G.L., Emilio Bombardieri, Massimo Gasparini, et al.. (1987). Radioimmunodetection of melanoma. 31(1). 37–38. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact